Navigation Links
VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
Date:8/19/2007

ished research also forms the basis for VisEn's filed inter partes re-examination of the '851 patent.

"The field of fluorescence in vivo imaging is already beginning to have a profound impact on the life-science and healthcare space," said Kirtland Poss, President and CEO of VisEn. "Since VisEn's founding, it has been our mission to work with leaders in the field to enable and support continued innovation, application, and expansion of the very best in fluorescence in vivo imaging technology. While we generally respect the contributions of Caliper/Xenogen to the field of bioluminescence imaging, we believe it is clear, and also fundamentally understood in the industry, that that the basic methods of fluorescence in vivo imaging were well known and in use before the priority date of the '851 patent, and therefore that the claims therein are clearly invalid. With this action today, our continued aim is to enable customers and partners in the space to innovate, apply and expand the power of fluorescence in vivo imaging broadly in their programs worldwide. We are confident that the rich history of optical in vivo imaging and the clear sequence of prior art references speak for themselves, and we look forward to continuing the development of all aspects of molecular imaging along with the leadership in the field."

The inter partes re-examination action filed with the USPTO is a matter of public record, and is posted at http://www.visenmedical.com .

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. The Company also works directly with large pharmace
'/>"/>

SOURCE VisEn Medical, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire-USNewswir...ntists, policy makers, and funders today convened ...tive funding strategies at the inaugural Partneri...ashington-based center of the Milken Institute, co...sector collaborations needed to turn a scientific ...
(Date:12/2/2009)..., , LIBREVILLE, Gabon, December 2 /PRN...in Africa: Everyone,s Problem and Heritage" ,...diversity, 2-3 June 2010 the,Gabonese Republic is ...(Gabon) on the issue of safeguarding biological re... by government and state leaders, ministers,scien...
(Date:12/2/2009)..., , SINGAPORE, Dec. 2 ...on its novel oral JAK2 inhibitor, SB1518, at The A...and Exposition in New Orleans. ,, Data will be ... dose-escalation trial of SB1518 detailing its saf...mic (PK/PD) profile in dose levels ranging from 10...
(Date:12/2/2009)..., , SHANGHAI, Dec. 2 /PRNewswire-Asi...es; markets are in turmoil and uncertainty is part...hat the pharma industry has been,relatively immune... take a,vacation. , During the midst of t...iant Johnson & Johnson inaugurated an R&D ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
...rmaceuticals, Inc. (Nasdaq: TPPH ) announced toda...ovember 5, 2007 at 12:00 p.m. Eastern Time,(10:00 ...quarter 2007,financial results and provide a compa...regarding its second quarter financial results on ...rticipate in the conference call, please dial 800-...
...y of Pediatrics National Conference & ...AST NORRITON, Pa., Oct. 29 Tengion,Inc., a leader...ndings from,a preclinical study being presented to...tional Conference and Exhibition demonstrate the a...estore bladder function in a,well- established pre...
...unced today that it,has received the European CE M...p(TM) System for cervical cancer screening. The CE..., safety and environmental requirements,that ensur...therlands, the,registration will allow the system ...r countries around the world that recognize the CE...
Other Biology Technology:Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening 2
(Date:12/2/2009)...N - A team comprised of undergraduate students fro...honors in a national poster contest hosted by the ...ng (ISPE). , The annual contest highlights the r...t month at the ISPE Annual Meeting in San Diego, C...f a Posterior Criciate Ligament Tensioning Device,...
(Date:12/2/2009)...w study on the smokeless tobacco product called mo...entists in Minnesota to urge the tobacco industry ...s content of carcinogens. Their study is published... in Toxicology . It reports that this category of ... of certain toxic and cancer-causing substances. C...
(Date:12/2/2009)...le-walled nanotubescylinders of carbon about a nan...ntial applications such as ultrastrong fibers, ele...orage components for fuel cells. Thanks to a new d...e of Standards and Technology (NIST) and five part...: detection and destruction of an aggressive form ...
Breaking Biology News(10 mins):Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Reconstructive Plastic Surgery Patients Honored for Giving Back 59589 1Reconstructive Plastic Surgery Patients Honored for Giving Back 59589 2Reconstructive Plastic Surgery Patients Honored for Giving Back 59589 3Reconstructive Plastic Surgery Patients Honored for Giving Back 59589 4Video 3A Cities and States Around the U S Recognize October 13 as Metastatic Breast Cancer Awareness Day 59586 1Video 3A Cities and States Around the U S Recognize October 13 as Metastatic Breast Cancer Awareness Day 59586 2Video 3A Cities and States Around the U S Recognize October 13 as Metastatic Breast Cancer Awareness Day 59586 3Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2
...n that seems to be pivotal in lifting depression h...funded by the National Institutes of Health,s Nati...eficient in this protein, called p11, display depr... amounts behave as if they have been treated with ... a Rockefeller University neuroscientist who recei...
...ledge that one disease may prevent the onset of an...cowpox vaccines can prevent smallpox dates back to...iatrics at the Mattel Children,s Hospital at UCLA,... ways that one disease prevents another. , His fi...lic influences should be considered when looking f...
...ts have discovered that a stem cell factor overexp...llowing brain injury promotes tumor survival by in... in the April issue of Cancer Cell, examines the i...sues and may have substantial significance for des...most lethal types of tumor, malignant gliomas. , ...
Other Biology News:Nobelist discovers antidepressant protein in mouse brain 2Nobelist discovers antidepressant protein in mouse brain 3UCLA paper examines how one disease may prevent another 2Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2
...terone Receptor (PR) Competitor Assay Kits are ide...ceptor binding compounds using fluorescence polari...n of glutathione transferase to the ligand binding...)] and a proprietary, fluorescently tagged progest...
Organic Acid Analysis Standard, 6 vials from Bio-Rad
...anys Molecular Imaging Systems group announces the...Imaging Systems, featuring high resolution cooled ...ce, luminescence, radiographic and chromogenic ima...nd 10x optical zoom lens provides spatial resoluti...
...particle shape and size analyzer offering a wide d... simplicity in mind. It is comprised of a chemical...l bench. The system is completely computer control...r different applications such as dry or where smal...
Biology Products: